Outcomes of patients with severe and critical COVID-19 treated with dexamethasone: a prospective cohort study
Autor: | Sandra Rajme-López, María F González-Lara, Carla M Roman-Montes, Alejandra Martínez-Valenzuela, Francisco E Dardón-Fierro, Edgar Ortiz-Brizuela, Bernardo A Martinez-Guerra, Karla M Tamez-Torres, Carla Medrano-Borromeo, Alfredo Ponce-de-León, José Sifuentes-Osornio |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2021 |
Předmět: |
Male
medicine.medical_specialty Multivariate analysis Coronavirus disease 2019 (COVID-19) Epidemiology Coronaviruses medicine.medical_treatment Critical Illness Immunology Clinical Decision-Making Corticosteroid treatment Infectious and parasitic diseases RC109-216 Comorbidity Microbiology Severity of Illness Index Dexamethasone corticosteroids Virology Internal medicine Drug Discovery Medicine Humans Hospital Mortality Prospective cohort study Mexico Aged Mechanical ventilation business.industry SARS-CoV-2 COVID-19 Disease Management General Medicine Middle Aged QR1-502 COVID-19 Drug Treatment Hospitalization Infectious Diseases Treatment Outcome Parasitology Female business Lower mortality Cohort study medicine.drug Research Article |
Zdroj: | Emerging Microbes & Infections article-version (VoR) Version of Record Emerging Microbes and Infections, Vol 11, Iss 1, Pp 50-59 (2022) |
ISSN: | 2222-1751 |
Popis: | BACKGROUND Dexamethasone implementation for COVID-19 management represented a milestone but data regarding its impact and safety has not been consistently reproduced. OBJECTIVE We aimed to evaluate in-hospital mortality before and after the implementation of corticosteroid treatment (CS-T) for severe and critical COVID-19. METHODS We conducted a cohort study that included patients admitted with severe and critical COVID-19. Primary outcome was death during hospitalization. Secondary outcomes included length of stay (LOS), need for invasive mechanical ventilation (IMV), time to IMV initiation, IMV duration and development of hospital acquired infections (HAIs). Bivariate, multivariate and propensity-score matching analysis were performed. RESULTS Among 1,540 patients, 688 (45%) received CS-T. Death was less frequent in the CS-T group (18% vs 31%, p |
Databáze: | OpenAIRE |
Externí odkaz: |